株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

世界のバイオシミラーメーカー上位25社 (2019年)

Top 25 Biosimilar Drug Manufacturers 2019

発行 Visiongain Ltd 商品コード 288682
出版日 ページ情報 英文 220 Pages
納期: 即日から翌営業日
価格
本日の銀行送金レート: 1GBP=139.32円で換算しております。

ご注意:
Single UserとDepartmentalライセンスは、DRM (デジタル著作権管理システム) 付PDFになります。制限内容は、上記ライセンスの[?]アイコンをクリックしてご確認ください。

Back to Top
世界のバイオシミラーメーカー上位25社 (2019年) Top 25 Biosimilar Drug Manufacturers 2019
出版日: 2019年04月17日 ページ情報: 英文 220 Pages
概要

世界のバイオシミラー市場の2018~2028年のCAGR (複合年間成長率) は40%にも達する、と予測されています。多数の生物製剤メーカーが2012~2019年に「特許の崖」を迎え、主力製品の特許が満了となることが、バイオシミラー企業の業績拡大を促す要因となっています。

当レポートでは、世界のバイオシミラー市場について取り上げ、市場の概要と予測、主要製品の概要、国別動向、および上位企業25社のプロファイルなどをまとめています。

第1章 分析概要

第2章 バイオシミラー:世界市場の予測

  • イントロダクション:生物製剤とバイオシミラー
    • 生物製剤:定義と概要
    • バイオシミラー:定義と概要
    • バイオシミラーとジェネリック医薬品の違い
  • 世界のバイオシミラー市場 (今後11年間分)
  • 世界市場の収益額:概要 (今後11年間分)
  • バイオシミラー:可能性の実現、市場促進要因
  • バイオシミラー:市場抑制要因

第3章 主要な生物製剤・バイオシミラー:概要

  • Humira:製品概要
  • Remicade:製品概要
  • Enbrel:製品概要
  • Aranesp:製品概要
  • Rituxan:製品概要

第4章 米国・欧州・イスラエルの主なバイオシミラーメーカー

  • Sandoz
    • バイオシミラー製品
    • バイオシミラーの市場予測 (今後11年間分)
    • 研究開発 (R&D) パイプラインと将来展望
  • Teva Pharmaceuticals
  • Hospira (Pfizer)
  • STADA Arzneimittel
  • Mylan
  • 米国のその他の企業
    • Impax Laboratories Inc.
    • Bristol-Myers Squibb
    • Merck & Co.
    • Eli Lilly
  • 欧州のその他の企業
    • BioXpress Therapeutics
    • Medice Arzneimittel Putter GmbH & Co. KG
    • Finox Biotech

第5章 中国の主なバイオシミラーメーカー

  • 3SBio
  • Qilu Pharmaceutical
  • Shanghai Fosun Pharmaceuticals
  • Tonghua Dongbao
  • Beijing ShuangLu Pharmaceuticals
  • 中国のその他の企業

第6章 インドの主なバイオシミラーメーカー

  • Biocon
  • Dr. Reddy's Laboratories
  • Wockhardt
  • Zydus Cadila
  • Ranbaxy (Sun Pharma)
  • Reliance Life Sciences
  • Intas Biopharmaceuticals
  • インドのその他の企業
    • Emcure Pharmaceuticals
    • Shreya Life Sciences
    • Cipla
    • Shantha Biotechnics

第7章 ラテンアメリカの主なバイオシミラーメーカー

  • Probiomed
  • Biosidus
  • Amega Biotech
  • ラテンアメリカのその他の企業
    • Bionovis
    • Orygen Biotecnologia
    • Recepta

第8章 他の国々 (RoW) の主なバイオシミラーメーカー

  • Celltrion
  • LG Life Sciences
  • Dong-A
  • Bioton
  • Biocad
  • その他の企業
    • Gedeon-Richter
    • Egis Pharmaceuticals
    • JCRファーマ
    • 日本化薬
    • 協和キリン富士フイルムバイオロジクス
    • 第一三共

第9章 バイオシミラー市場の定性分析

  • SWOT分析
    • バイオシミラー産業・市場の強み・弱み・機会・脅威
  • STEP分析
    • 社会的・技術的・経済的・政治的要因

第10章 分析結果

付録

図表

List of Tables

  • Table 2.1: Global Biosimilar Market: Revenue Forecast ($bn), Annual Growth (%), CAGR (%), 2018-2028
  • Table 2.2: Finalised US FDA Biosimilar Guidelines
  • Table 3.1: Humira Biologic Analysis, 2018
  • Table 3.2: Remicade Biologic Analysis, 2018
  • Table 3.3: Enbrel Biologic Analysis, 2018
  • Table 3.4: Aranesp: Biologic Analysis, 2018
  • Table 3.5: Rituxan: Biologic Analysis, 2018
  • Table 4.1: Sandoz: Company Overview, 2018
  • Table 4.2: Sandoz: Biosimilars Product Portfolio, 2018
  • Table 4.3: Sandoz: Biosimilar Products Forecast: Revenue ($bn), AGR (%), CAGR (%), 2018-2028
  • Table 4.4: Sandoz: Biosimilar Developments Overview, 2018
  • Table 4.5: Teva: Company Overview, 2018
  • Table 4.6: Teva: Biosimilars Overview, 2018
  • Table 4.7: Teva Pharmaceuticals: Biosimilar Products Forecast: Revenue ($bn), AGR (%), CAGR (%), 2018-2028
  • Table 4.8: Hospira: Company Overview, 2018
  • Table 4.9: Hospira: Company Overview, 2018
  • Table 4.10: Hospira: Biosimilar Developments Overview, 2018
  • Table 4.13: Stada Arzneimittel: Company Overview, 2018
  • Table 4.14: Stada Arzneimittel: Biosimilars Overview, 2018
  • Table 4.15: Stada Arzneimittel: Biosimilar Developments Overview, 2018
  • Table 4.16: Mylan: Company Overview, 2018
  • Table 4.17: Mylan: Biosimilars Overview, 2018
  • Table 4.18: Mylan Pharmaceuticals: Biosimilar Products Forecast: Revenue ($bn), AGR (%), CAGR (%), 2018-2028
  • Table 4.19: Mylan: Biosimilar Developments Overview, 2018
  • Table 4.20: Impax Laboratories: Company Overview, 2018
  • Table 4.21: Bristol-MyersSquibb: Company Overview, 2018
  • Table 4.22: Merck & Co.: Company Overview, 2018
  • Table 4.23: Merck & Co.: Biosimilars Product Pipeline, 2018
  • Table 4.24: Eli Lilly: Company Overview, 2018
  • Table 4.25: Eli Lilly: Biosimilars Product Portfolio, 2018
  • Table 4.26: BioXpress Therapeutics: Company Overview, 2018
  • Table 4.27: Medice Arzneimittel Pütter: Company Overview, 2018
  • Table 4.28: Finox Biotech: Company Overview, 2018
  • Table 5.1: 3SBio: Company Overview, 2018
  • Table 5.2: 3SBio: Biosimilars Overview, 2018
  • Table 5.3: 3SBio: Biosimilar Developments Overview, 2018
  • Table 5.4: Qilu Pharmaceutical: Company Overview, 2018
  • Table 5.5: Qilu Pharmaceutical: Biosimilars Overview, 2018
  • Table 5.6: Qilu Pharmaceutical: Biosimilar Developments Overview, 2018
  • Table 5.7: Shanghai Fosun: Company Overview, 2018
  • Table 5.8: Shanghai Fosun: Biosimilars Overview, 2018
  • Table 5.9: Shanghai Fosun: Biosimilar Developments Overview, 2018
  • Table 5.10: Tonghua Dongbao: Company Overview, 2018
  • Table 5.11: Tonghua Dongbao: Biosimilars Overview, 2018
  • Table 5.12: Tonghua Dongbao: Biosimilar Developments Overview, 2018
  • Table 5.13: Beijing ShuangLu: Company Overview, 2018
  • Table 5.14: Beijing ShuangLu: Biosimilars Overview, 2018
  • Table 5.15: Beijing ShuangLu: Biosimilar Developments Overview, 2018
  • Table 5.16: Shanghai CP Guojian: Company Overview, 2018
  • Table 5.17: Zhejiang Hisun: Company Overview, 2018
  • Table 5.18: Innovent Biologics: Biosimilars Overview, 2018
  • Table 5.19: Shanghai Celgen Biopharmaceutical: Company Overview, 2018
  • Table 6.1: Biocon: Company Overview, 2018
  • Table 6.2: Biocon: Biosimilars Product Portfolio, 2018
  • Table 6.3: Biocon: Biosimilar Products Forecast: Revenue ($bn), AGR (%), CAGR (%), 2016-2021
  • Table 6.4: Biocon: Biosimilars Pipeline, 2018
  • Table 6.5: Dr. Reddy's Laboratories: Company Overview, 2018
  • Table 6.6: Dr. Reddy's Laboratories: Biosimilar Products, 2018
  • Table 6.7: Dr. Reddy's Laboratories: Biosimilars Pipeline, 2018
  • Table 6.8: Wockhardt: Company Overview, 2018
  • Table 6.9: Wockhardt: Biosimilar Products, 2018
  • Table 6.10: Wockhardt: Biosimilars Pipeline, 2018
  • Table 6.11: Zydus Cadila: Company Overview, 2018
  • Table 6.12: Zydus Cadila: Biosimilars Product Portfolio, 2018
  • Table 6.13: Zydus Cadila: Biosimilars Pipeline, 2018
  • Table 6.14: Ranbaxy: Company Overview, 2018
  • Table 6.15: Ranbaxy: Biosimilars Product Portfolio, 2018
  • Table 6.16: Zenotech: Biosimilars Pipeline, 2018
  • Table 6.17: Reliance Life Sciences: Company Overview, 2018
  • Table 6.18: Reliance Life Sciences: Biosimilar Products, 2018
  • Table 6.19: Reliance Life Sciences: Biosimilars Pipeline, 2018
  • Table 6.20: Intas Biopharmaceuticals: Company Overview, 2018
  • Table 6.21: Intas Biopharmaceuticals: Biosimilar Products Portfolio, 2018
  • Table 6.22: Intas Biopharmaceuticals: Biosimilars Pipeline, 2018
  • Table 6.23: Emcure Pharmaceuticals: Company Overview, 2018
  • Table 6.24: Shreya Life Sciences: Company Overview, 2018
  • Table 6.25: Cipla: Company Overview, 2018
  • Table 6.26: Shantha Biotechnics: Company Overview, 2018
  • Table 7.1: Probiomed: Company Overview, 2018
  • Table 7.2: Probiomed Biosimilars Product Portfolio, 2018
  • Table 7.3: Biosidus: Company Overview, 2018
  • Table 7.4: Biosidus: Biosimilars Product Portfolio, 2018
  • Table 7.5: Biosidus: Biosimilars Pipeline, 2018
  • Table 7.6: Amega Biotech: Company Overview, 2018
  • Table 7.7: Amega Biotech: Biosimilars Product Portfolio , 2018
  • Table 7.8: Bionovis: Company Overview, 2018
  • Table 7.9: Orygen Biotechnologia: Company Overview, 2018
  • Table 7.10: Recepta: Company Overview, 2018
  • Table 8.1: Celltrion: Company Overview, 2018
  • Table 8.2: Celltrion: Biosimilars Overview, 2018
  • Table 8.3: LG Life Sciences: Company Overview, 2018
  • Table 8.4: LG Life Sciences: Biosimilars Product Portfolio, 2018
  • Table 8.5: LG Life Sciences: Biosimilars Pipeline, 2018
  • Table 8.6: Dong-A: Company Overview, 2018
  • Table 8.7: Dong-A: Biosimilar Product Portfolio, 2018
  • Table 8.8: Dong-A: Biosimilar Pipeline, 2018
  • Table 8.9: Bioton: Company Overview, 2018
  • Table 8.10: Bioton: Biosimilars Product Portfolio, 2018
  • Table 8.11: Biocad: Company Overview, 2018
  • Table 8.12: Biocad: Biosimilars Product Portfolio, 2018
  • Table 8.13: Biocad: Biosimilars Pipeline, 2018
  • Table 8.14: Gedeon-Richter: Company Overview, 2018
  • Table 8.15: Egis Pharmaceuticals: Company Overview, 2018
  • Table 8.16: JCR Pharmaceuticals: Company Overview, 2018
  • Table 8.17: Nippon Kayaku: Company Overview, 2018
  • Table 8.18: Fujifilm Kyowa Kirin Biologics: Company Overview, 2018
  • Table 8.19: Daiichi Sankyo: Company Overview, 2018

List of Figures

  • Figure 1.1: Biosimilars Market Segmentation, 2018
  • Figure 2.1: Global Biosimilar Market: Revenue Forecast ($bn), 2018-2028
  • Figure 2.2: Global Biosimilar Market Drivers, 2018
  • Figure 2.3: Global Biosimilar Market Restraints, 2018
  • Figure 4.1: Sandoz: Biosimilar Products Revenue Forecast ($bn), 2018-2028
  • Figure 4.2: Teva Pharmaceuticals: Biosimilar Products Revenue Forecast ($bn), 2018-2028
  • Figure 4.3: Mylan Pharmaceuticals: Biosimilar Products Revenue Forecast ($bn), 2018-2028
  • Figure 6.1: Biocon: Biosimilar Products Revenue Forecast ($bn), 2018-2028
  • Figure 9.1: SWOT Analysis of the Biosimilars Market, 2018
  • Figure 9.2: STEP Analysis of the Biosimilars Market, 2018

COMPANIES LISTED:

  • 3SBio
  • AbbVie
  • Actavis
  • Alvotech
  • Amega Biotech
  • Amgen
  • Apotex
  • Aragen Bioscience
  • ASKA Pharmaceuticals
  • Beijing ShuangLu Pharmaceuticals
  • Biocad
  • Biocon
  • Biogen inc.
  • Biolab Sanus Farmacêutica
  • Bionovis
  • Biopartners
  • Biosidus
  • Bioton
  • Biovel Life Sciences
  • BioXpress Therapeutics
  • Boehringer Ingelheim
  • Bristol-Myers Squibb
  • Celltrion
  • Cipla
  • CITIC Group
  • Coherus Biosciences
  • CP Guojian
  • Cristalía
  • Daiichi Sankyo
  • Dong-A
  • Dr. Reddy's Laboratories
  • Egis Pharmaceuticals
  • Eisai
  • Eli Lilly
  • Emcure Pharmaceuticals
  • Epirus Pharmaceuticals
  • Eurofarma
  • Finox Biotech
  • Fosun Pharma
  • Fuji Pharma
  • Fujifilm Kyowa Kirin Biologics
  • Gan & Lee Pharmaceutical
  • Gedeon-Richter
  • Genentech
  • Genzyme
  • Hetero Drugs Limited
  • Hospira
  • Impax Laboratories Inc.
  • Innovent Biologics
  • Intas Biopharmaceuticals
  • JCR Pharmaceuticals
  • Kyowa Kirin
  • LG Life Sciences
  • Libbs Farmacêutica
  • Marvel Life Sciences
  • Medice Arzneimittel Pütter GmbH & Co. KG
  • Merck & Co.
  • Merck KGaA
  • Merck Serono
  • Mitsubishi Tanabe
  • MJ Biopharm
  • MJ Bioton Life Sciences
  • Mochida
  • Momenta Pharmaceuticals
  • Mylan
  • Nippon Kayaku
  • NovaQuest
  • Novo Nordisk
  • Orgyen
  • Orygen Biotechnologia
  • Pfizer
  • Pharmstandard
  • Probiomed
  • Qilu Pharmaceutical
  • Ranbaxy
  • Recepta
  • Reliance Life Sciences
  • Samsung Bioepsis
  • Samsung biologics
  • Sandoz
  • Sanofi
  • SciGen
  • Shanghai Celgen Biopharmaceuticals
  • Shanghai CP Guojian
  • Shanghai Fosun Pharmaceuticals
  • Shanghai Lansheng Guojian Pharmaceutical Co. Ltd.
  • Shantha Biotechnics
  • Shenyang Sunshine
  • Shreya Life Sciences
  • Sicor Biotech
  • Sidus Pharmaceutical Group
  • STADA Arzneimittel
  • Teva Pharmaceutical Industries Ltd
  • Tonghua Dongbao
  • Wanbang Biopharmaceuticals
  • Wockhardt
  • Xiamen Amoytop Biotech
  • Zhejiang Hisun
  • Zydus Cadila

List of Organizations Mentioned in the Report:

  • Agência Nacional de Vigilância Sanitária (ANVISA)
  • Chinese Food and Drug Administration (CFDA)
  • European Medicine Agency (EMA)
  • European Union (EU)
  • Food and Drug Administration (FDA)
  • Korean Food and Drug Administration (KFDA)
  • Ministry of Health, Labour and Welfare (MHLW)
  • National Autonomous University of Mexico (UNAM)
  • National Council for Science and Technology (CONACyT)
  • South Korea's Ministry of Food and Drug Safety (MFDS)
目次
Product Code: PHA0414

Title:
Top 25 Biosimilar Drug Manufacturers 2019
Humira, Remicade, Enbrel, Aranesp, Rituxan, Sandoz, Teva, Hospira, Pfizer, STADA Arzneimittel, Mylan, 3SBio, Qilu Pharmaceutical, Shanghai Fosun Pharmaceutical, Biocon, Dr. Reddy's Laboratories, Probiomed, Biosidus, Celltrion, LG Life Sciences, Other Companies.

Visiongain forecasts that the biosimilar drugs market will grow with a CAGR of 40% from 2018 to 2028. Growth is expected to be rapid during the first-half of the forecasted period due to the patent cliff from years 2012-2019, which will see the patent expiry of many of the most popular biologics in the world. The opening of the US market due to clearer defined guideline regarding biosimilars will lead to greater penetration of biosimilars in this lucrative market, which will help the rapid growth and development of the market.

How this report will benefit you

Read on to discover how you can exploit the future business opportunities emerging in this sector.

In this brand new 220-page report you will receive 117 charts- all unavailable elsewhere.

The 220-page report provides clear detailed insight into the top 25 biosimilar drugs manufacturers. Discover the key drivers and challenges affecting the market.

Report Scope

Discussion and overview of the leading biologic and biosimilar products, covering:

  • Humira
  • Remicade
  • Enbrel
  • Aranesp
  • Rituxan
  • Adalimumab biosimilars
  • Infliximab biosimilars
  • Etanercept biosimilars
  • Darbepoetin Alpha biosimilars
  • Rituximab biosimilars

Profiles of leading biosimilar companies based in the US, Western Europe and Israel:

  • Hospira
  • Mylan
  • Sandoz
  • STADA Arzneimittel
  • Teva Pharmaceutical Industries
  • Other companies in these regions

Profiles of leading biosimilar companies based in China:

  • 3SBio
  • Beijing ShuangLu Pharmaceuticals
  • Qilu Pharmaceutical
  • Shanghai Fosun Pharmaceuticals
  • Tonghua Dongbao
  • Other companies in China

Profiles of leading biosimilar companies based in India:

  • Biocon
  • Dr. Reddy's Laboratories
  • Intas Biopharmaceuticals.
  • Ranbaxy
  • Reliance Life Sciences
  • Wockhardt
  • Zydus Cadila
  • Other companies in China

Profiles of leading biosimilar companies based in Latin America:

  • Probiomed
  • Biosidus
  • Amega Biotech
  • Other companies in Latin America

Profiles of leading biosimilar companies based in the rest of the world:

  • Celltrion
  • LG Life Sciences
  • Dong-A
  • Bioton
  • Biocad
  • Other companies in the rest of the world

The report provides information and discussion on:

  • Company overview & analysis
  • Biosimilars Products
  • Future Outlook
  • Technologies and activities
  • R&D Pipelines

Qualitative analysis: a SWOT and STEP analysis of the biosimilars market. Discussion on factors that drive and restrain the biosimilars market.

Key questions answered by this report:

  • What are its drivers and restraints of the biosimilar drugs market?
  • What are the leading biosimilar products in the market and which companies manufacture them?
  • Who are the leading biosimilars companies?
  • What are their products, developmental candidates and therapeutic applications?
  • What is the status of the clinical trials they are undergoing?
  • What are the latest news and developments from those companies?
  • What other biopharmaceutical companies seem promising within the regions we analyse, having potential to succeed in biosimilar drug development, production and marketing?
  • What are leading companies' biosimilar products and what candidates are in their R&D pipelines?
  • What are the social, technological, economic and political forces affecting the world biosimilars market?

Visiongain's study is intended for anyone requiring commercial analyses for the Top 25 Biosimilar Drugs Manufacturers 2019. You find data, trends and predictions.

Buy our report today Top 25 Biosimilar Drug Manufacturers 2019: Humira, Remicade, Enbrel, Aranesp, Rituxan, Sandoz, Teva, Hospira, Pfizer, STADA Arzneimittel, Mylan, 3SBio, Qilu Pharmaceutical, Shanghai Fosun Pharmaceutical, Biocon, Dr. Reddy's Laboratories, Probiomed, Biosidus, Celltrion, LG Life Sciences, Other Companies.

Visiongain is a trading partner with the US Federal Government.

Table of Contents

1. Report Overview

  • 1.1. Overview of the Top Biosimilar Drug Manufacturers
  • 1.2. Why You Should Read This Report
  • 1.3. How This Report Delivers
  • 1.4. Main Questions Answered by This Analytical Study
  • 1.5. Who is This Report For?
  • 1.6. Methodology
  • 1.7. Frequently Asked Questions (FAQ)
  • 1.8. Associated Visiongain Reports
  • 1.9. About Visiongain

2. Biosimilar Drugs: World Market Forecast to 2028

  • 2.1. Introduction to Biologics and Biosimilars
    • 2.1.1. Biologic Drugs Definition and Overview
    • 2.1.2. Biosimilars Drugs Definition and Overview
    • 2.1.3. How do Biosimilars Differ from Generics?
  • 2.2. The World Biosimilar Market, 2018-2028
  • 2.3. Overall World Biosimilars Revenue Forecast, 2018-2028
  • 2.4. Biosimilars-Realising their Potential, Market Drivers
    • 2.4.1. Biosimilar Approval Pathways and Regulations
    • 2.4.2. India Releases New Biosimilar Development Guidelines
    • 2.4.3. Russia: Lack of Regulatory Framework Works Well in the Short Term
    • 2.4.4. ‘Pharma 2020' Initiative
    • 2.4.5. South Korean Market has benefitted from Early Biosimilar Guidelines
    • 2.4.6. Chinese FDA Publishes Finalised Biosimilar Guidelines in 2016
    • 2.4.7. Brazil: ANVISA's Biosimilar Regulations Are Similar the EMA's
    • 2.4.8. The Outlook for Biosimilars in the EU
    • 2.4.9. The Outlook for Biosimilars in Japan
    • 2.4.10. Emerging Markets for Biosimilars
    • 2.4.11. Start-up Pressure on Market Leaders
    • 2.4.12. The Patent Cliff for Biologics
  • 2.5. Biosimilars: Market Restraints
    • 2.5.1. Market Fragmentation for Biosimilar Products
    • 2.5.2. Innovative Biologics-Rendering Biosimilars Useless?
    • 2.5.3. Biobetters-A Growing Threat
    • 2.5.4. BREXIT and Trump Election-A Rising Political Threat

3. Leading Biologic & Biosimilar Products: Overview, 2018

  • 3.1. Humira: Product Overview
    • 3.1.1. Adalimumab Biosimilars-Zydus Cadila
    • 3.1.2. Adalimumab Biosimilars-Amgen-Actavis
    • 3.1.3. Adalimumab Biosimilars-Sandoz
    • 3.1.4. Adalimumab Biosimilars-Momenta Pharmaceuticals
    • 3.1.5. Adalimumab Biosimilars-Pfizer
    • 3.1.6. Adalimumab Biosimilars-Boehringer Ingelheim
    • 3.1.7. Adalimumab Biosimilars-Samsung Biologics and Biogen Inc.
  • 3.2. Remicade: Product Overview
    • 3.2.1. Infliximab Biosimilar-Epirus Pharmaceuticals & Ranbaxy
    • 3.2.2. Infliximab Biosimilar-Celltrion & Hospira & Alvogen
  • 3.3. Enbrel: Product Overview
    • 3.3.1. Etanercept Biosimilar-Cipla & Shanghai CP Guojian
    • 3.3.2. Etanercept Biosimilar-Daiichi Sankyo & Coherus Biosciences
  • 3.4. Aranesp: Product Overview
    • 3.4.1. Darbepoetin Alpha Biosimilar-Dr. Reddy's Laboratories
    • 3.4.2. Darbepoetin Alpha Biosimilar-Cipla & Hetero Drugs Limited
    • 3.4.3. Darbepoetin Alpha Biosimilar-Hospira
  • 3.5. Rituxan: Product Overview
    • 3.5.1. Rituximab Biosimilar-Sandoz
    • 3.5.2. Rituximab Biosimilar-Amgen
    • 3.5.3. Rituximab Biosimilar-Boehringer Ingelheim
    • 3.5.4. Rituximab Biosimilar-Dr. Reddy's Laboratories
    • 3.5.5. Rituximab Biosimilar-Pfizer
    • 3.5.6. Rituximab Biosimilar-Difficulties Seen in Trials

4. Leading Biosimilar Manufacturers in the United States, Western Europe and Israel

  • 4.1. Sandoz-Company Overview & Analysis
    • 4.1.1. Sandoz Biosimilar Products
    • 4.1.2. Sandoz Biosimilars Market Forecast, 2018-2028
    • 4.1.3. Sandoz Biosimilars R&D Pipeline & Future Outlook
      • 4.1.3.1. GP2018-Adalimumab Biosimilar
      • 4.1.3.2. GP2015-Etanercept Biosimilar
      • 4.1.3.3. GP2013-Rituximab Biosimilar
      • 4.1.3.4. HX575-Epoetin-alfa Biosimilar
      • 4.1.3.5. EP2006-Zarzio (Filgrastim Biosimilar)
  • 4.2. Teva Pharmaceuticals-Company Overview & Analysis
    • 4.2.1. Teva Biosimilar Products
    • 4.2.2. Teva Biosimilar Market Forecast, 2018-2028
    • 4.2.3. Teva Biosimilar Pipeline & Future Outlook
  • 4.3. Hospira (Pfizer)-Company Overview & Analysis
    • 4.3.1. Hospira Biosimilar Products
    • 4.3.2. Hospira Biosimilars Pipeline & Future Strategies
      • 4.3.2.1. Retacrit
      • 4.3.2.2. Celltrion Partnerships
      • 4.3.2.3. NovaQuest Partnership
  • 4.4. STADA Arzneimittel-Company Overview & Analysis
    • 4.4.1. STADA Biosimilar Products
    • 4.4.2. STADA Biosimilars Pipeline & Future Outlook
      • 4.4.2.1. Biosimilar Pegfilgrastim
      • 4.4.2.2. Biosimilar Rituximab
      • 4.4.2.3. Biosimilar Teriparatide
  • 4.5. Mylan-Company Biosimilar & Analysis
    • 4.5.1. Mylan Biosimilar Products
    • 4.5.2. Mylan Biosimilar Market Forecast, 2018-2028
    • 4.5.3. Mylan Biosimilars Pipeline & Future Outlook
      • 4.5.3.1. Mylan and Momenta-Biosimilars Product Development Programme
      • 4.5.3.2. Biosimilar Insulin Glargine
      • 4.5.3.3. A Series of Biosimilar Monoclonal Antibodies
      • 4.5.3.4. Biosimilar Insulin Lispro & Aspart
  • 4.6. Other Biosimilars Companies in the US
    • 4.6.1. Impax Laboratories Inc.-Company Overview & Analysis
    • 4.6.2. Bristol-Myers Squibb-Company Overview & Analysis
    • 4.6.3. Merck & Co.-Company Overview & Analysis
    • 4.6.4. Eli Lilly-Company Overview & Analysis
  • 4.7. Other Biosimilar Companies in Europe
    • 4.7.1. BioXpress Therapeutics-Company Overview & Analysis
    • 4.7.2. Medice Arzneimittel Pütter GmbH & Co. KG-Company Overview & Analysis
    • 4.7.3. Finox Biotech-Company Overview & Analysis

5. Leading Biosimilar Manufacturers in China

  • 5.1. 3SBio-Company Overview & Analysis
    • 5.1.1. 3SBio Biosimilar Products
    • 5.1.2. 3SBio Biosimilars Pipeline & Future Outlook
      • 5.1.2.1. Second-generation rhEPO products
      • 5.1.2.2. Nadroparin Calcium
  • 5.2. Qilu Pharmaceutical-Company Overview & Analysis
    • 5.2.1. Qilu Pharmaceutical Biosimilar Products
    • 5.2.2. Qilu Pharmaceutical Biosimilars Pipeline & Future Outlook
      • 5.2.2.1. Extensive Pipeline Developments
      • 5.2.2.2. Etanercept Biosimilar
      • 5.2.2.3. Other Biosimilars in Pipeline
  • 5.3. Shanghai Fosun Pharmaceuticals-Company Overview & Analysis
    • 5.3.1. Shanghai Fosun Pharmaceuticals Biosimilar Products
    • 5.3.2. Shanghai Fosun Pharmaceuticals Biosimilars Pipeline & Future Strategy
      • 5.3.2.1. Trastuzumab Biosimilar
      • 5.3.2.2. Rituximab Biosimilar
      • 5.3.2.3. Acquisitions and Investments
  • 5.4. Tonghua Dongbao-Company Overview & Analysis
    • 5.4.1. Tonghua Dongbao Biosimilar Products
    • 5.4.2. Tonghua Dongbao Biosimilars Pipeline & Future Strategies
      • 5.4.2.1. Biosimilar Insulin Analogues
      • 5.4.2.2. Investments in New Production Plant
  • 5.5. Beijing ShuangLu Pharmaceuticals-Company Overview & Analysis
    • 5.5.1. Beijing ShuangLu Pharmaceuticals Biosimilar Products
    • 5.5.2. Beijing ShuangLu Pharmaceutical Biosimilars Pipeline & Future Outlook
  • 5.6. Other Biosimilars Companies in China
    • 5.6.1. Shanghai CP Guojian-Company Overview & Analysis
    • 5.6.2. Zhejiang Hisun-Company Overview & Analysis
    • 5.6.3. Innovent Biologics-Company Overview & Analysis
    • 5.6.4. Shanghai Celgen Biopharmaceutical-Company Overview & Analysis

6. Leading Biosimilar Manufacturers in India

  • 6.1. Biocon-Company Overview & Analysis
    • 6.1.1. Biocon Biosimilar Products
    • 6.1.2. Biocon Biosimilars Market Forecast, 2018-2028
    • 6.1.3. Biocon Biosimilars Pipeline & Future Outlook
      • 6.1.3.1. Biosimilar Bevacizumab
      • 6.1.3.2. Biosimilar Adalimumab
      • 6.1.3.3. Biosimilar Pegfilgrastim
      • 6.1.3.4. Biosimilar Trastuzumab
      • 6.1.3.5. Biosimilar Etanercept
      • 6.1.3.6. Biosimilar Recombinant Human Insulin
      • 6.1.3.7. Biosimilar Insulin Glargine
      • 6.1.3.8. Other Biosimilar Insulin
  • 6.2. Dr. Reddy's Laboratories-Company Overview & Analysis
    • 6.2.1. Dr. Reddy's Laboratories Biosimilar Products
    • 6.2.2. Dr. Reddy's Laboratories Biosimilars Pipeline & Future Outlook
      • 6.2.2.1. Merck Serono Collaboration
      • 6.2.2.2. Increasing Focus on Emerging Markets
  • 6.3. Wockhardt-Company Overview & Analysis
    • 6.3.1. Wockhardt Biosimilar Products
    • 6.3.2. Wockhardt Biosimilars Pipeline & Future Outlook
  • 6.4. Zydus Cadila-Company Overview & Analysis
    • 6.4.1. Zydus Cadila Biosimilar Products
    • 6.4.2. Zydus Cadila Biosimilars Pipeline & Future Outlook
      • 6.4.2.1. Biosimilar Interferon beta-1b
      • 6.4.2.2. Oncology Biosimilars
      • 6.4.2.3. Inflammation Biosimilars
      • 6.4.2.4. Thrombolytic Biosimilars
      • 6.4.2.5. Fertility Biosimilars
  • 6.5. Ranbaxy (Sun Pharma)-Company Overview & Analysis
    • 6.5.1. Ranbaxy Biosimilar Products
    • 6.5.2. Ranbaxy Biosimilars Pipeline & Future Outlook
  • 6.6. Reliance Life Sciences-Company Overview & Analysis
    • 6.6.1. Reliance Life Sciences Biosimilar Products
    • 6.6.2. Reliance Life Sciences Biosimilars Pipeline & Future Outlook
  • 6.7. Intas Biopharmaceuticals-Company Overview & Analysis
    • 6.7.1. Intas Biopharmaceuticals Biosimilar Products
    • 6.7.2. Intas Biopharmaceuticals Biosimilars Pipeline & Future Outlook
      • 6.7.2.1. Biosimilar Pegylated Interferon
      • 6.7.2.2. Biosimilar Etanercept
      • 6.7.2.3. Biosimilar Ranibizumab
      • 6.7.2.4. Overseas Opportunities
  • 6.8. Other Indian Biosimilars Companies
    • 6.8.1. Emcure Pharmaceuticals-Company Overview & Analysis
    • 6.8.2. Shreya Life Sciences-Company Overview & Analysis
    • 6.8.3. Cipla-Company Overview & Analysis
    • 6.8.4. Shantha Biotechnics-Company Overview & Analysis

7. Leading Biosimilar Manufacturers in Latin America

  • 7.1. Probiomed-Company Overview & Analysis
    • 7.1.1. Probiomed Biosimilar Products
    • 7.1.2. Probiomed Biosimilars Pipeline & Future Strategies
  • 7.2. Biosidus-Company Overview & Analysis
    • 7.2.1. Biosidus Biosimilar Products
    • 7.2.2. Biosidus Biosimilars Pipeline & Future Strategies
  • 7.3. Amega Biotech-Company Overview and Analysis
    • 7.3.1. Amega-Biosimilar Products
    • 7.3.2. Amega Biotech Biosimilars Pipeline & Future Strategies
  • 7.4. Other Biosimilars Companies in Latin America
    • 7.4.1. Bionovis-Company Overview & Analysis
    • 7.4.2. Orygen Biotecnologia-Company Overview & Analysis
    • 7.4.3. Recepta-Company Overview & Analysis

8. Leading Biosimilar Manufacturers in the Rest of the World

  • 8.1. Celltrion-Company Overview & Analysis
    • 8.1.1. Celltrion Biosimilar Products
    • 8.1.2. Celltrion Biosimilars Pipeline & Future Strategies
      • 8.1.2.1. Trastuzumab Biosimilar
      • 8.1.2.2. Rituximab Biosimilar
      • 8.1.2.3. Four Further Development mAb Biosimilar
  • 8.2. LG Life Sciences-Company Overview & Analysis
    • 8.2.1. LG Life Sciences Biosimilar Products
    • 8.2.2. LG Life Science Biosimilars Pipeline & Future Strategies
  • 8.3. Dong-A-Company Overview & Analysis
    • 8.3.1. Dong-A Biosimilar Products
    • 8.3.2. Dong-A Biosimilars Pipeline & Future Strategies
      • 8.3.2.1. DA-3803-hCG Biosimilar
      • 8.3.2.2. DA-3031-Pegylated Filgrastim Biosimilar
      • 8.3.2.3. DA-3880-Darbepoetin alpha Biosimilar
      • 8.3.2.4. DA-3111-Trastuzumab Biosimilar
      • 8.3.2.5. DA-3113-Adalimumab Biosimilar
      • 8.3.2.6. 3853-Etanercept Biosimilar
      • 8.3.2.7. DA-3808-Recombinant Factor VIII Biosimilar
  • 8.4-Company Overview & Analysis
    • 8.4.1. Bioton's Biosimilar Products
    • 8.4.2. Bioton's Biosimilars Pipeline & Future Strategies
  • 8.5. Biocad-Company Overview & Analysis
    • 8.5.1. Biocad's Biosimilar Products
    • 8.5.2. Biocad's Biosimilars Pipeline & Future Strategies
  • 8.6. Other Biosimilars Companies in the RoW
    • 8.6.1. Gedeon-Richter-Company Overview & Analysis
    • 8.6.2. Egis Pharmaceuticals-Company Overview & Analysis
    • 8.6.3. JCR Pharmaceuticals-Company Overview & Analysis
    • 8.6.4. Nippon Kayaku-Company Overview & Analysis
    • 8.6.5. Fujifilm Kyowa Kirin Biologics-Company Overview & Analysis
    • 8.6.6. Daiichi Sankyo-Company Overview & Analysis

9. Qualitative Analysis of Biosimilars Market: 2018-2028

  • 9.1. SWOT Analysis of the Global Biosimilars Industry and Market
    • 9.1.1. Strengths
      • 9.1.1.1. Savings in Healthcare Costs
      • 9.1.1.2. Strong Pipeline-Innovation and Growth of the Biosimilars Market
      • 9.1.1.3. Entry of Biosimilars Into the US market
    • 9.1.2. Weaknesses
      • 9.1.2.1. R&D Cost-Pricing Companies Out of Biosimilars?
      • 9.1.2.2. Developing Market-Biosimilars Still Niche
      • 9.1.2.3. Unclear Regulations for Biosimilars
    • 9.1.3. Opportunities
      • 9.1.3.1. Patent Expiry for Branded Biologics
      • 9.1.3.2. Increase in Prevalence of Chronic Diseases
      • 9.1.3.3. Innovation-New Technology Driving Biosimilar Growth
      • 9.1.3.4. Focus on Biosimilar Monoclonal Antibodies and Insulin
    • 9.1.4. Threats
      • 9.1.4.1. Stricter Regulations for Biosimilar Manufacturers
      • 9.1.4.2. Lawsuits-Patent Protection from Innovator Biologics
      • 9.1.4.3. Biobetters-Removing the Need for Biosimilars?
  • 9.2. STEP Analysis of the Global Biosimilars Industry and Market: 2018-2027
    • 9.2.1. Social Factors
      • 9.2.1.1. Global Healthcare-An Ambitious Aim?
      • 9.2.1.2. Raising Awareness will Lead to Greater Product Adoption
    • 9.2.2. Technological Factors
      • 9.2.2.1. Innovation Driven-Growing Manufacturing Efficiency
      • 9.2.2.2. High Technological Expertise Needed
    • 9.2.3. Economic Factors
      • 9.2.3.1. R&D for Biosimilar Development-Cost Barriers
      • 9.2.3.2. Healthcare Savings-Cutting Spending and Costs
    • 9.2.4. Political Factors
      • 9.2.4.1. Government Influence-Funding for Biosimilar Industry?
      • 9.2.4.2. International Cooperation Required
      • 9.2.4.3. Regularly Updated Guideline Will Benefit Developers

10. Conclusions

  • 10.1. Market Leaders Among Biosimilar Manufacturers
  • 10.2. Will Sandoz Retain its Position as Market Leader?
  • 10.3. Which Companies Are Best Placed to Lead in Future?
  • 10.4. Big Pharma Companies Will Try Gain Market Entry
  • 10.5. Contribution of Chinese and Indian Companies will Grow
  • 10.6. Strong R&D Pipeline-Driver for Growth
  • 10.7. Concluding Remarks

Appendices

  • Associated Visiongain Reports
  • Visiongain Report Sales Order Form
  • About Visiongain
  • Visiongain report evaluation form
Back to Top